S&P Capital IQ Initiates Coverage on Yew Bio-Pharm Group in Standard & Poor's Factual Stock Reports
NEW YORK, Aug. 19, 2013 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Yew Bio-Pharm Group.
Yew Bio-Pharm Group, Inc. (YEWB), through its operating entity, Harbin Yew Science and Technology Development Co., Ltd., grows and sells yew trees, sells yew raw materials used in the manufacture of traditional Chinese medicine (TCM), and makes and sells products made from yew timber in China. Raw material from the species of yew tree that the company grows contains taxol, and TCM containing taxol has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. Products made from yew trees include potted yew trees for display in homes and offices, and handicrafts.
The company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them.
The company operates in three reportable business segments: the TCM raw materials segment, consisting of the production and sale of yew raw materials used in the manufacture of TCM; the yew tree segment, consisting of the growth and sale of yew tree seedlings and mature trees, including potted miniature yew trees; and the handicrafts segment, consisting of the manufacture and sale of furniture and handicrafts made of yew timber. All of the company's operations are conducted in the People's Republic of China.
During the three months ended June 30, 2013, Yew Bio-Pharm sold approximately 7,880 kg (17,336 lb) of TCM raw materials as compared to approximately 7,050 kg (15,510 lb) of TCM raw materials in the three months ended June 30, 2012. During the six months ended June 30, 2013, Yew Bio-Pharm sold approximately 13,207 kg (29,066 lb) of TCM raw materials as compared to approximately 11,400 kg (25,080 lb) of TCM raw materials in the six months ended June 30, 2012. During the three months ended June 30, 2013, Yew Bio-Pharm sold approximately 38,000 pieces of yew seedlings and trees as compared to approximately 88,000 pieces of yew seedlings and trees in the three months ended June 30, 2012. During the six months ended June 30, 2013, Yew Bio-Pharm sold approximately 218,000 pieces of yew seedlings and trees as compared to approximately 180,000 pieces of yew seedlings and trees in the six months ended June 30, 2012.
Yew Bio-Pharm sells yew trees primarily to state-owned enterprises and private businesses for reforestation in Heilongjiang Province and Jilin Province, in Northeast China.
Standard & Poor's Factual Stock Report coverage on Yew Bio-Pharm Group will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.yewchina.com for additional information.
About Standard & Poor's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com.
CCG Investor Relations
John Harmon, CFA, Senior Account Manager
Tel: +86 (10) 8573 1014 (Beijing)
S&P Capital IQ
Richard Albanese, 212-438-3647
Michael Privitera, 212-438-6679
SOURCE S&P Capital IQ
More by this Source
S&P Capital IQ Initiates Coverage on BioCorRx Inc. in S&P Capital IQ Factual Stock Reports
Apr 03, 2014, 10:37 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.